Today's Peptide News — August 23, 2026

A new Yale study reported this week upends a core assumption about how GLP-1 drugs curb appetite. Rather than simply silencing the brain's hunger signals, semaglutide appears to activate agouti-related peptide (AgRP) neurons in the hypothalamus — the very cells best known for driving the urge to eat. When researchers disrupted these neurons in female mice, the animals still ate less during treatment, but the deeper metabolic response needed to sustain weight loss weakened, and they regained the lost weight within about 15 days. The effect hinged on rising cyclic AMP signaling in the area postrema, a brainstem region tied to appetite.

The finding matters because it reframes what a successful obesity drug actually does: appetite suppression alone may not explain durable fat loss, and the metabolic arm of GLP-1 action could be the harder target to hit. It also sits in tension with a 2025 Northwestern study that concluded semaglutide and tirzepatide silence AgRP neurons rather than switch them on, leaving the mechanism genuinely contested. For PeptideWiki, this is a strong explainer post on semaglutide's mechanism of action — an angle framed around "why the hunger-neuron debate changes how we think about GLP-1 durability" would give readers the current state of a live scientific argument.

Researchers publishing in Nature Communications describe a compact linear antimicrobial peptide built from four repeating (D-tryptophan)-(D-arginine)-(D-lysine) units. The all-D-amino-acid design gives it high stability against protease degradation while retaining potent activity against multidrug-resistant pathogens including MRSA and Klebsiella pneumoniae. In a mouse model of bacterial pneumonia, the peptide showed meaningful therapeutic efficacy, and it also blunted lipopolysaccharide-induced lung injury. Crucially, it acts through several mechanisms at once — membrane targeting plus non-lytic routes such as DNA binding, reactive-oxygen-species accumulation, ATP depletion, and metabolic interference.

What makes this stand out is not just that it kills resistant bacteria but that it showed low propensity to drive new resistance and could even restore sensitivity to conventional antibiotics. That combination — a resistance-alleviating, multi-mechanism peptide with in vivo lung efficacy — is exactly the profile the field has been chasing. For PeptideWiki, this is prime material for a post on D-amino-acid antimicrobial peptides, with an angle on how stereochemistry (using D-residues) buys both stability and resistance-breaking behavior in a way small-molecule antibiotics struggle to match.

A study co-led by Myriam Cotten at Oregon State University, combining wet-lab work with computational modeling from the NIH's National Heart, Lung, and Blood Institute, pins down the physical rules governing how antimicrobial peptides destroy bacterial membranes. The team characterized the pores these peptides carve into membranes and found a clear pattern: the most effective peptides form pores that are larger, more numerous, and stay open longer. That structural signature separates peptides that merely perturb a membrane from those that decisively rupture it.

The value here is design guidance. If pore geometry and lifetime predict potency, medicinal chemists can tune peptide sequences toward those properties rather than screening blindly — a meaningful lever as antimicrobial resistance is projected to cause tens of millions of deaths between 2025 and 2050. For PeptideWiki, this supports a mechanism-of-action explainer on membrane-disrupting peptides, with an angle on "what makes a good pore" and how that insight feeds rational antimicrobial peptide design.

A randomized Phase 2 trial published in Nature Medicine reports that aleniglipron, an oral GLP-1 receptor agonist, helped adults with obesity or overweight lose as much as 12.1% of body weight over 36 weeks at the highest dose, versus just 0.5% on placebo. Lower doses still produced 9.0% and 10.7% average reductions. Unlike injectable peptide GLP-1s such as semaglutide, aleniglipron is a small-molecule pill that can be taken with or without food, sidestepping the refrigeration, manufacturing, and access constraints that limit peptide injectables.

For a peptide-focused audience, the interesting tension is that the momentum in the GLP-1 field is increasingly toward non-peptide small molecules that mimic what peptides do — a competitive dynamic worth tracking. A PeptideWiki angle could contrast the injectable peptide incumbents against the emerging oral small-molecule challengers, using aleniglipron's data as the anchor for where oral GLP-1 efficacy currently sits.

Petrelintide, a once-weekly amylin analog developed by Zealand Pharma and partnered with Roche, delivered up to 10.7% mean weight loss through week 42 in the Phase 2 ZUPREME-1 trial of 493 people, against 1.7% on placebo. The tolerability profile drew particular attention: at the maximally effective dose there were no cases of vomiting and no discontinuations for gastrointestinal side effects, and 98% of participants in the top-responding cohort reached the maintenance dose. Topline results from ZUPREME-2, testing petrelintide in people with obesity or overweight and type 2 diabetes, are expected in the second half of 2026.

Amylin agonism is emerging as the most credible non-incretin lever in obesity, prized for smoother tolerability than GLP-1 monotherapy and for its potential in combination regimens. For PeptideWiki, petrelintide warrants a dedicated profile page, with an angle on amylin analogs as the "next mechanism" in weight management and why their gentler side-effect profile could matter for long-term adherence.

Retatrutide, a single peptide engineered to activate the GIP, GLP-1, and glucagon receptors simultaneously, has produced the largest weight loss yet reported in a Phase 3 obesity trial — above 28% — with a regulatory filing anticipated in late 2026 and approval unlikely before 2027 or 2028. The added glucagon-receptor arm is thought to raise energy expenditure on top of the appetite and glycemic effects of the GLP-1 and GIP components, helping explain the step-change in efficacy over dual agonists.

The retatrutide story illustrates how far multi-receptor peptide engineering has come: one molecule tuned to hit three targets at calibrated ratios. For PeptideWiki, this is a natural explainer on triple agonists and receptor polypharmacology, with an angle on how stacking incretin and glucagon activity in a single peptide backbone is redrawing the ceiling on pharmacological weight loss.

Researchers at Karolinska Institutet and Umeå University, drawing on up to 14 years of follow-up from Sweden's Stockholm-Gotland screening program covering more than 376,000 people, report that active participation in fecal-blood screening was associated with a 43% lower risk of dying from colorectal cancer. Even an invitation to screen, regardless of uptake, was linked to a 26% reduction. The program mails a kit for a home stool sample, tests for hidden blood, and offers colonoscopy follow-up when blood is detected. The findings were published in JAMA Network Open.

The result is a strong endorsement of simple, low-cost, at-home screening as a population-level tool against one of the most common cancers, reinforcing the case for broad participation in organized screening programs.

A study published in The American Journal of Human Genetics analyzed gene activity across more than 1.25 million immune cells from 982 people and identified over 1,000 genetic "switches" that behave differently between the sexes. Immune cells from women showed higher baseline activity in inflammatory pathways tied to autoimmune disease, and the team pinpointed variants driving female-biased expression of two genes linked to systemic lupus erythematosus — a condition roughly nine times more common in women than men. Men carried more monocyte "first responder" cells, while women had higher levels of adaptive B and T cells.

The work offers a mechanistic handle on a long-standing epidemiological puzzle and underscores why both sexes must be represented in immunology and drug research, since disease biology and treatment response can diverge along sex lines.

New research highlighted this month identifies a brain mechanism that helps explain the pull of high-fat foods, pointing to specific circuitry that reinforces overeating rather than a simple failure of willpower. The finding adds to a growing picture of appetite as a set of distinct, targetable neural pathways rather than a single on-off switch.

Mapping the circuits behind fat preference could eventually inform therapies that dampen the drive to overconsume calorie-dense foods, complementing the metabolic approaches that dominate current obesity treatment.